Risks
4 risks
Risk Intelligence
US Tariff Uncertainty
View Risks →Ajanta Pharma Limited — Q4 FY25
Ajanta Pharma delivered a solid Q4 FY25 with consolidated revenue of INR 1,170 crore (+11% YoY) and PAT of INR 225 crore (+11% YoY).
bullish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Ajanta Pharma delivered a solid Q4 FY25 with consolidated revenue of INR 1,170 crore (+11% YoY) and PAT of INR 225 crore (+11% YoY). Growth was driven by branded generics (74% of revenue, +12% YoY), particularly India (+13%) and Africa (+17%). The US generics business rebounded strongly (+25% YoY) on new product launches. EBITDA margin contracted to 25% (vs 26% in Q4 FY24) due to higher personnel costs from MR additions and gratuity policy changes. Management guided for FY26 revenue growth of low-teens in branded generics and high-teens in US generics, with EBITDA margins around 28% (similar to FY25). Key risks include US tariff uncertainty (Section 232 investigation) and continued unpredictability in the Africa institutional business, which declined 53% in Q4.
अजंता फार्मा ने वित्त वर्ष 2025 की चौथी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल आय 1,170 करोड़ रुपये रही, जो पिछले साल से 11% अधिक है। मुनाफा 225 करोड़ रुपये रहा, जो 11% बढ़ा। कंपनी की ज्यादातर कमाई ब्रांडेड जेनेरिक दवाओं (74%) से हुई, जिसमें भारत में 13% और अफ्रीका में 17% की बढ़त रही। अमेरिका में नई दवाओं के लॉन्च से कारोबार 25% बढ़ा। मुनाफा दर (EBITDA मार्जिन) 25% रही, जो पिछले साल 26% थी, क्योंकि कर्मचारियों पर खर्च बढ़ा। कंपनी को अगले साल भारत में 10-12% और अमेरिका में 15-18% बढ़ोतरी की उम्मीद है। मुनाफा दर 28% के आसपास रहने का अनुमान है। जोखिमों में अमेरिकी टैरिफ और अफ्रीका में अनिश्चितता शामिल है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Branded Generic Revenue Growth (FY25)
INR 3,394 crore
+15% YoY
Branded generics contributed 74% of total revenue, driven by strong performance across India, Asia, and Africa.
US Generics Revenue Growth (Q4)
INR 325 crore
+25% YoY
US business rebounded sharply due to new product launches in H2 FY25; full-year growth was 9%.
India Business Growth (FY25)
INR 1,452 crore
+11% YoY
India outperformed IPM by 300 bps; volume growth nearly double the market. New therapies (gynae, nephro) added.
Africa Institutional Revenue Decline (Q4)
INR 28 crore
-53% YoY
Africa institutional business continued to decline sharply due to unpredictable donor funding; now only 3% of revenue.
What Changed vs Last Quarter
NEW
FY26 ANDA Filings: 10-12 filings
Management expects to file 10-12 ANDAs in FY26, with a robust pipeline and several products in advanced stages.
UPDATED
FY26 Revenue Growth: Branded generics low-teens, US generics high-teens
Management expects branded generic business to grow in low teens and US generics in high teens, driven by new product launches and market share gains.
UPDATED
FY26 EBITDA Margin ~28% (similar to FY25)
CFO guided EBITDA margin around 28% plus/minus 1% for FY26, similar to FY25 level, as higher personnel costs offset gross margin improvements.
UPDATED
FY26 Capex ~INR 300 crore
Capital expenditure for FY26 is estimated at around INR 300 crore, including maintenance capex and ongoing projects like the liquid plant at Pithampur.
DROPPED
R&D spend at 5% of revenue for FY25
R&D expenses are expected to remain at 5% of total revenue for the fiscal year.
NEW RISK
US Tariff Uncertainty
The US has initiated a Section 232 investigation into pharmaceutical imports, which could lead to tariffs. Management has a directional plan but no clarity on outcome.
NEW RISK
Elevated Personnel Costs Impacting Margins
Personnel costs rose 21% in FY25 due to MR additions and gratuity policy changes, pressuring EBITDA margins. Normalization expected in FY26 but full-year impact remains.
NEW RISK
Ophthalmology Segment Slowdown
Ophthalmology grew only 5% in FY25, below company average. Management attributed it to market trends but offered no specific mitigation plan.
RISK GONE
U.S. generic price erosion and launch delays
U.S. generics growth is dependent on new product launches and limited competition; any delays or higher-than-expected price erosion could impact growth.
RISK GONE
Margin pressure from new therapy investments
Entry into gynecology and nephrology in India and CNS in Asia will increase SG&A and personnel costs, potentially pressuring near-term margins.
RISK GONE
Tax rate increase in FY27
Management indicated tax rate may rise from 24% to ~25% in FY27 as some exemptions expire, impacting net profitability.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q2 FY25, Q3 FY24, Q3 FY25, Q4 FY24
U.S. generics growth is dependent on new product launches and limited competition; any delays or higher-than-expected price erosion could impact growth.
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q2 FY25, Q3 FY24, Q3 FY25
Management expects EBITDA margin to remain around 28% for the full fiscal year, with quarterly fluctuations of 50-100 bps.
Mentioned in Q1 FY24, Q1 FY25, Q2 FY25, Q3 FY25, Q4 FY24
Capital expenditure for FY25 is estimated at about INR 225 crore, including maintenance capex.
Mentioned in Q1 FY25, Q2 FY24, Q3 FY24
Overall revenue expected to grow in low teens, with branded generics mid-teens, US mid-single digit, and Africa institutional degrowth.
Mentioned in Q1 FY24, Q2 FY24
Chantix launch is delayed to Q4 FY24 or Q1 FY25; any further delay could impact US revenue expectations.
Fast read
Guidance and risk preview
Management expects branded generic business to grow in low teens and US generics in high teens, driven by new product launches and market share gains.
The US has initiated a Section 232 investigation into pharmaceutical imports, which could lead to tariffs.
View Risks →